Pharmaceutical At the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, US pharma giant Pfizer announced much anticipated results from the PALOMA-1 study, a randomized Phase II study of palbociclib (PD-0332991) in combination with letrozole which, while meeting its primary endpoint, disappointed investors, with the firm’s shares falling 3% to $31.16 by close yesterday. 8 April 2014